Neurosense Therapeutics is trading at $2.60, up 11.58%, in line with a biotech-sector rally. - The XBI is up 2.18% during the regular session. - On October 26, NeuroSense announced an agreement to pursue U.S. patient access to investigational PrimeC; initial revenue is targeted for the first half of 2027. - Reporting does not establish the October 26 announcement as the direct cause of the October 27 gain. No company-specific headlines were listed that day, leaving the sector trend as the clearest available context.